Join Now

Category Archives: BioUtah News

Life Sciences Day on the Hill 2025

By Natalie Themm | Published January 30, 2025

The Capitol Rotunda was filled with exhibits from over 25 local life sciences companies.

Also posted in Life Sciences Events | | Tagged | Comments Off on Life Sciences Day on the Hill 2025

Kelvyn Cullimore Joins KSL Radio’s Inside Sources

By admin | Published January 24, 2025

SALT LAKE CITY, January 23, 2025—Today BioUtah president and CEO Kelvyn Cullimore joined KSL Radio’s Inside Sources to discuss the life sciences industry in the State of Utah. Hosted by Maura Carabello and Adam Gardiner, Inside Sources daily broadcast covers political issues affecting Utah. Today, Carabello and Gardiner interviewed Cullimore to spotlight Utah’s life sciences industry and […]

| Comments Off on Kelvyn Cullimore Joins KSL Radio’s Inside Sources

Ultradent Donating to Southern California Fire Relief

By Natalie Themm | Published January 14, 2025

Ultradent Donating to Southern California Fire Relief

| Tagged | Comments Off on Ultradent Donating to Southern California Fire Relief

Canyon Labs Announces Strategic Acquisition of iuvo BioScience’s Lab Services and Consulting Businesses to Expand End-to-End Development Solutions

By Natalie Themm | Published January 9, 2025

Transaction positions iuvo BioScience for continued growth as an industry leader in ophthalmic clinical research

| Tagged | Comments Off on Canyon Labs Announces Strategic Acquisition of iuvo BioScience’s Lab Services and Consulting Businesses to Expand End-to-End Development Solutions

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

By Natalie Themm | Published January 9, 2025

Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway

| Tagged | Comments Off on Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

By Natalie Themm | Published January 9, 2025

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

| Tagged | Comments Off on Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

By Natalie Themm | Published January 9, 2025

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

| Tagged | Comments Off on MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

By Natalie Themm | Published January 9, 2025

Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs

| Tagged | Comments Off on M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

ARUP Offers New Assay To Detect Influenza A (H5) Virus

By admin | Published January 3, 2025

SALT LAKE CITY, January 3, 2025—ARUP Laboratories today launched a new assay for the detection and subtyping of influenza A (H5) virus. This test will aid in the evaluation of individuals who may have been exposed to highly pathogenic avian influenza (HPAI) A virus, also known as H5N1 or bird flu. In early 2024, an outbreak […]

| Comments Off on ARUP Offers New Assay To Detect Influenza A (H5) Virus

Sethera Therapeutics Completes First Funding Round

By Natalie Themm | Published January 2, 2025

Sethera Therapeutics Completes First Funding Round

| Tagged | Comments Off on Sethera Therapeutics Completes First Funding Round

Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

By Natalie Themm | Published January 2, 2025

Data from Dual-Acting Oral Biologic Show Promising Safety and Efficacy Profile

| Tagged | Comments Off on Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

CancerVax Passes First Test with Flying Colors

By Natalie Themm | Published January 2, 2025

Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells

| Tagged | Comments Off on CancerVax Passes First Test with Flying Colors

A Special Thanks To Our Legacy and Platinum Elite Members